NAS
CRMD icon

Nykredit A/S’s CorMedix CRMD Stock Holding History

Nykredit A/S’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Buy
+1,318
New +$10.4K ﹤0.01% 1865

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Nykredit A/S's CRMD Position: Q2 2026 in Review

Nykredit A/S opened a new position in CorMedix (CRMD) in Q2 2026: 1,318 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #1865 among its holdings.

123 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Nykredit A/S held 1,318 shares of CorMedix worth $10.3K as of Q2 2026.
  • CorMedix was a new Nykredit A/S position in Q2 2026.
  • CorMedix made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1865 holding.
  • 123 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.